Background: Mutations in the PLCE1 gene encoding phospholipase C epsilon 1 (PLCε1)
INTRODUCTION
Nephrotic syndrome (NS) results from disruption of the renal filtration barrier composed of interdigitating podocyte foot processes linked by the slit diaphragm, and endothelial cells separated from podocytes by the glomerular basement membrane. It is characterized by massive proteinuria, hypoalbuminemia, hyperlipidemia, edema and podocyte foot process effacement by electron microscopy. NS is classified as steroid-sensitive (SSNS) or steroidresistant (SRNS) and mutations in several genes, mostly coding for podocyte proteins, have been identified as causing SRNS in humans. Although kidney biopsy discloses focal and segmental glomerulosclerosis (FSGS) lesions for most patients with SRNS, 1 a smaller proportion of children may present a particularly severe renal histological pattern named diffuse mesangial sclerosis (DMS) with an early presentation and a poor renal prognosis.
DMS is characterized by mesangial expansion and sclerosis that evolves toward obliteration of the capillary lumen and contraction of the glomerular tuft. This type of renal histology has been described as part of syndromes such as Denys-Drash syndrome or Pierson syndrome, caused by mutations in the WT1 and LAMB2 genes, respectively. More recently, PLCE1 mutations have been found as a novel cause of DMS. 2 Involvement of the PLCE1 gene (MIM*608414) in NS has been found using a combination of homozygosity mapping and cDNA microarrays from rat glomeruli. In the original series described by Hinkes et al., 2 truncating PLCE1 mutations were identified in 12 siblings from six families diagnosed with early-onset NS and DMS while a homozygous missense mutation was identified in two siblings with a later onset of disease and FSGS (Nephrotic syndrome, type 3; NPHS3 -MIM#610725); until now, these individuals were the only reported cases of FSGS secondary to PLCE1 mutations. Subsequently, mutations in PLCE1 have been demonstrated as a major cause of isolated DMS, identified in 28.6% of 35 families in a worldwide cohort. 3 Although PLCE1 mutations typically lead to a severe phenotype, full and sustained treatment responses 4 have been reported in two individuals with truncating mutations 2 and a pathogenic homozygous mutation have also been found in a phenotypically completely normal adult. 4 This suggests that other factors may modify the effect of PLCE1 mutations.
PLCE1 gene encodes the phospholipase C epsilon 1 (PLCε1).
Members of the phosphoinositide-specific phospholipase C (PLC) family catalyze the hydrolysis of membrane phospholipids to generate the second messenger molecules inositol 1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG) that initiate intracellular pathways of cell growth and differentiation. shown that PLCε1 is regulated by H-Ras (via RA1 and RA2 domains) and also interacts with IQGAP1 (IQ motif-containing GTPase-activating protein) and BRAF. 2 5-7 In order to better define the phenotype spectrum of patients bearing PLCE1 mutations, we performed mutational analysis and clinical follow-up of a large worldwide cohort of patients with either familial or sporadic SRNS. In addition, we aimed to determine the role of candidate genes, including other PLC genes, as modifiers of disease in families for which both symptomatic and asymptomatic members had homozygous PLCE1 mutations. 
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MATERIALS AND METHODS
Patients
PLCE1 molecular analyses
Genomic DNA specimens were collected with informed consent and isolated from peripheral blood using standard procedures. Linkage of familial cases to the PLCE1 locus was assessed 6 using four polymorphic microsatellite markers spanning 5. 
Finally, the complete coding sequence and exon-intron boundaries of the genes not excluded by the whole genome wide scan or by microsatellite markers analysis were sequenced as 
Statistical analysis
All values are expressed as means ± standard error or median (range). Comparisons between two continuous variables were performed using the Mann-Whitney test. All tests were two sided. P-values <0.05 were considered significant. Statistical analyses were performed using GraphPad Prism software version 5.01.
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RESULTS
Patients characteristics
Patients characteristics are summarized in 
Identification of PLCE1 Mutations
Microsatellite markers analysis excluded linkage to the PLCE1 locus in 43 families.
Therefore, results were compatible with linkage to the PLCE1 locus in 25 families as evidenced by homozygosity for the polymorphic markers flanking the PLCE1 locus. Diseasecausing mutations were found in 12 families, comprising a total of 18 patients (Table 3) .
Among sporadic cases, homozygous PLCE1 mutations were identified in 3 patients. Most were homozygous truncating mutations (nonsense or frameshift mutations), although compound heterozygote missense mutations (p.E1386V/p.P1890L) were detected in two siblings and a homozygous missense mutation (p.H1407D) was detected in one sporadic case.
The p.E1386V was predicted to be a possibly pathogenic mutation (Polyphen score 1.94) and involved a very highly conserved amino-acid from fishes to humans. The p.P1890L and p.H1407D were predicted to be probably pathogenic mutations with a Polyphen score of 2.55 and 2.50, respectively, involving amino-acids conserved from C-elegans to humans, and 
Identification of asymptomatic individuals bearing homozygous PLCE1 mutations
Surprisingly, segregation analysis revealed that 3 unaffected individuals belonging to 3 unrelated families were also found to bear, in the homozygous state, the mutations identified Segregation analysis revealed that the father, who was also born from consanguineous parents, was homozygous for the mutation. Although he had presented hypertension and mild proteinuria as a teenager, his renal evaluation, at 46 years of age, was normal.
Search for modifier genes
To understand this phenomenon, we ought to identify mutations or variants in other genes that could modulate the clinical phenotype. We hypothesized a protective effect arising from other members of the phospholipase C family in the asymptomatic individuals. Alternatively, In this regards, we identified three unaffected individuals carrying the same homozygous mutation as their affected relatives, a finding particularly unusual for disease of recessive inheritance. One other previous case report of a family of 3 affected siblings with DMS also showed that the asymptomatic father, who was himself born from consanguineous parents, had the same homozygous PLCE1 mutation as his affected children. 4 These data are also reminiscent of the unusual progression of two patients with DMS in the original description of PLCE1 mutations who seemed to respond to steroid or cyclosporin therapy. 2 The above observations raise the possibility of oligogenic inheritance, with either a third deleterious mutation in a second gene explaining the appearance of a renal phenotype in patients bearing two PLCE1 mutations or the presence of a protective modifier allele, which could compensate for the PLCE1 dysfunction in asymptomatic individuals. Although oligogenic inheritance has been suggested in several cases of renal diseases, [12] [13] [14] it is in only very rare cases that asymptomatic individuals presented two pathogenic mutations in one gene in contrast to affected individuals bearing an additional third mutation in a second gene. 15 Effect of modifiers genes could also explain the absence of obvious renal phenotype in the Plce1 knock-out mouse model, developed on a mixed C57/B6 X 129/S6 genetic background. Based on the preceding observations, we ought to identify mutations or variants in other genes that could explain the absence of renal phenotype in some patients with PLCE1 mutation. We first speculated a compensatory protective effect arising from other members of the PLC family in the unaffected individuals since the common role of these proteins is to initiate intracellular signaling through the generation of the second messenger molecules IP3
and diacylglycerol. Interestingly, some mouse models of PLC genes develop a renal phenotype, including increased kidney weight, polycystic kidneys, renal dysplasia, 15 glomerulosclerosis or signs of glomerulonephritis (Table 1) . Moreover, PLC-γ1 has been shown to play a key-role in the podocyte slit diaphragm. PLC-γ1 binds to phosphorylated nephrin, the main component of the slit, leading to PLC-γ1 activation and subsequent increase in IP3, and triggering of Ca2+ intracellular response. 19 In our study, we did not identify a PLC candidate that was mutated in a recessive or dominant fashion in the affected individuals and not in the asymptomatic relative, or the reverse. We then used the same approach for candidate genes that are known to interact directly or indirectly with PLCε1 such as IQGAP1, BRAF and NPHS1. IQGAP1 is a known scaffold protein of the mitogen-activated protein (MAP) kinase pathway 20 and interacts with PLCε1, 2 nephrin 21 and BRAF. 22 BRAF, which has been involved in various cancers, 23 belongs to the RAF family of genes and binds HRas. 24 It has also been implicated in the MAP kinase pathway and is considered as a third interaction partner of PLCε1, 7 in addition to H-ras and IQGAP-1. In the present study, IQGAP1, BRAF and NPHS1 genes did not appear to explain the phenotypic variability observed in our patients. However, our approach cannot exclude an effect of different PLC or PLC partner genes in the three different families. Finally, it has to be stressed that, to date, only very few homozygous PLCE1 mutations detected in asymptomatic individuals or patients that responded to therapy have been reported and, surprisingly, all of them are males. This is reminiscent of the unaffected SMN1-deleted individuals, which were all females, 16 and suggests the existence of gender-specific modifiers of disease.
In conclusion, PLCE1 mutations are frequently found in familial and sporadic DMS cases.
Although PLCE1 mutations had been rarely associated with FSGS, we showed that mutations in this gene are detected in a non-negligible proportion of familial FSGS cases without NPHS2 mutations. In this study, no clear genotype-phenotype correlation was present.
Although variants in other phospholipases C genes do not seem to explain the absence of 16 renal manifestations in some cases with PLCE1 mutations, we speculate that other modifier genes or environmental factors may play a role in the renal phenotype variability observed in individuals bearing PLCE1 mutations. More importantly, the clinical heterogeneity associated with PLCE1 mutations substantially increases the complexity of genetic counselling, including prenatal diagnosis, and needs to be considered in the discussion about renal prognosis with patients.
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2-4 10 The p.P382fsX387 mutation has been reported in one patient for which renal histology was not available. 2 We also found the p.Q1020X mutation in one patient without kidney biopsy.
* The p.R1246X mutation has been reported in DMS cases; 10 we also found the same mutation in both DMS and FSGS cases. DMS, diffuse mesangial sclerosis; FSGS, focal segmental glomerulosclerosis. 
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